Drug discovery targeting thyroid hormone receptor f3 (THRf3) for the treatment of liver diseases and other medical indications
文献类型：期刊论文
| 作者 | Wang, Kean2,3,4; Chen, Feiyang1,2; Wang, Jiang2; Liu, Hong1,3,4
|
| 刊名 | ACTA PHARMACEUTICA SINICA B
 |
| 出版日期 | 2025 |
| 卷号 | 15期号:1页码:35-51 |
| 关键词 | Thyroid hormone Thyroid hormone /3 receptor MASLD MASH THR/3 agonist |
| ISSN号 | 2211-3835 |
| DOI | 10.1016/j.apsb.2024.07.025 |
| 英文摘要 | Thyroid hormone receptors (THRs), a crucial nuclear receptor protein family, primarily consist of two categories: a receptors and /3 receptors. Among them, THR/3 is the primary subtype of thyroid hormone that confers benefits to the liver. In the last two decades, there have been efforts to develop THR/3 agonists that selectively yield beneficial effects on the liver, such as lowering triglycerides and cholesterol, while reducing adverse effects on the heart, muscle, and bone. This paper systematically reviews strategies to enhance the safety of THR/3 agonists for the treatment of MASH, with a focus on improving the selectivity of THRa and increasing the distribution of the drug in the liver. Additionally, we explore the potential application of this target in addressing other medical indications. (c) 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| WOS关键词 | NONALCOHOLIC FATTY LIVER ; AGONIST GC-1 ; HEPATOCYTE PROLIFERATION ; BETA AGONIST ; TR-BETA ; CELL-PROLIFERATION ; ENERGY-EXPENDITURE ; HEPATIC STEATOSIS ; MESSENGER-RNA ; RAT-LIVER |
| 资助项目 | National Natural Science Foundation of China[82130105] ; National Natural Science Foundation of China[22337003] ; National Natural Science Foundation of China[82121005] ; National Natural Science Foundation of China[82322063] ; National Natural Science Foundation of China[22177124] ; Lingang Laboratory[LG-GG-202403-01] ; Program of Shanghai Academic Research Leader[23XD1460300] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:001426698200001 |
| 出版者 | INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/316320]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Wang, Jiang; Liu, Hong |
| 作者单位 | 1.Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai 200031, Peoples R China 2.Lingang Lab, Shanghai 200031, Peoples R China 3.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China 4.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China |
| 推荐引用方式 GB/T 7714 | Wang, Kean,Chen, Feiyang,Wang, Jiang,et al. Drug discovery targeting thyroid hormone receptor f3 (THRf3) for the treatment of liver diseases and other medical indications[J]. ACTA PHARMACEUTICA SINICA B,2025,15(1):35-51. |
| APA | Wang, Kean,Chen, Feiyang,Wang, Jiang,&Liu, Hong.(2025).Drug discovery targeting thyroid hormone receptor f3 (THRf3) for the treatment of liver diseases and other medical indications.ACTA PHARMACEUTICA SINICA B,15(1),35-51. |
| MLA | Wang, Kean,et al."Drug discovery targeting thyroid hormone receptor f3 (THRf3) for the treatment of liver diseases and other medical indications".ACTA PHARMACEUTICA SINICA B 15.1(2025):35-51. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。